PROTAC-Based Therapeutics: From Design to Clinical Potential in Neurodegenerative Disease

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Neurodegenerative diseases involve progressive neuronal loss linked to misfolded proteins.
• Current therapies offer modest benefits due to issues like target specificity and brain penetration.

Purpose of the Study:

• To explore proteolysis-targeting chimaeras (PROTACs) as a novel therapeutic strategy for neurodegenerative disorders.
• To highlight the potential of PROTACs in degrading disease-specific proteins within neurons.

Main Methods:

• PROTACs utilize the ubiquitin-proteasome system for targeted protein degradation.
• PROTACs consist of a target-binding ligand, a linker, and an E3 ligase ligand.

Main Results:

• Preclinical studies demonstrate PROTACs' potential in targeting key pathogenic proteins (tau, α-synuclein, TDP-43, mHTT).
• Advancements include brain-permeable PROTAC formulations and understanding of CNS E3 ligase expression.

Conclusions:

• PROTACs offer a catalytic degradation approach, potentially allowing for reduced dosing.
• PROTAC-based therapies show significant therapeutic potential for neurodegenerative diseases, despite requiring further pharmacokinetic optimization.